The age of virtual pharma: Challenges and solutions for investor directors and successful boards

Jan 20, 2016 Tags: Biotech Pharma Investment

Public and private funding is supporting a large percentage of the R&D pipeline but there are too many potential products in development for pharma to license them all. Has the inability of pharma to absorb new assets through licensing and partnerships inhibited further investment? Smart small and mid-sized biotech companies have found new ways to work that will keep their boards and investors confident that there will be an exit.

Moderator: Flic Gabbay – Managing Partner and Co-Founder, TranScrip

  • Frank Armstrong – Xceleron, Summit Therapeutics, Redx and Faron Pharmaceuticals; TranScrip
  • Colin Broom – Nabriva Therapeutics
  • Michael Butler – Xceleron
  • Julia Gregory – ContraFect